Danaher DHR
Danaher Corporation is a diversified life sciences and diagnostics company that designs, manufactures, and markets medical products, laboratory instruments, and biotechnology solutions for customers in healthcare, research, and industrial sectors. Danaher shows earnings growth of 59.7% and an operating margin of 19.78%, but its valuation is demanding (P/E 40.02) and its ROE of 7.61% is modest. Financial health is solid (ND/EBITDA 2.93) and revenue growth of 5.5% is moderate, suggesting that the high earnings growth may not be sustainable.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Danaher Corporation is a diversified life sciences and diagnostics company that designs, manufactures, and markets medical products, laboratory instruments, and biotechnology solutions for customers in healthcare, research, and industrial sectors. Danaher shows earnings growth of 59.7% and an operating margin of 19.78%, but its valuation is demanding (P/E 40.02) and its ROE of 7.61% is modest. Financial health is solid (ND/EBITDA 2.93) and revenue growth of 5.5% is moderate, suggesting that the high earnings growth may not be sustainable.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.3 |
| Quality / Moat | 5.2 |
| Valuation | 3.6 |
| Growth | 7.1 |
| Dividend | 4.8 |
| Momentum | 5.9 |
| Risk & Context | 7.0 |
OVERALL SCORE: 5.5/10
Context and risks
Danaher operates in the diagnostics and life sciences sector, subject to moderate regulatory scrutiny in the US (FDA) and pricing pressure on medical devices. The country's governance risk is moderate, but there is no specific regulatory or geopolitical event materially affecting the company.
News considered in the analysis
- Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth — Artículo de análisis que destaca el crecimiento en detección sin etiquetas, una tecnología de nicho con potencial; refuerza la tesis de crecimiento pero no es un evento material nuevo.
- Stock Market Today: Dow Skids But Apple Eyes A Buy Point; Filing Says Trump Makes These Trades — Ruido de mercado general sin información específica sobre Danaher.
- Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better — Comparativa de opinión sin información nueva sobre los fundamentales de Danaher.
- 1 Mid-Cap Stock on Our Buy List and 2 We Avoid — Listículo genérico sin información específica y accionable sobre Danaher.
- 2 Unpopular Stocks That Should Get More Attention and 1 We Question — Listículo de opinión sin datos concretos que afecten a la valoración de Danaher.
Verdict: Hold. Business quality and growth are attractive, but the valuation already discounts optimistic expectations; wait for a better entry point or an upward revision of fundamentals.
Main risk: The main risk is the demanding valuation (P/E 40.02) in a rising interest rate environment, which could compress the multiple if earnings growth normalizes.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →